On the other hand, if the patient has unresectable neoplasia after neoadjuvant treatment, it was discussed that definitive treatment with concurrent chemo-radiation followed by durvalumab should be considered for patients with PD-L1 positive expression who do not progress on chemo-radiation treatment, following the results of the PACIFIC trial [24, 105, 106]. The gene discussed is CD274; the disease is neoplasm.